The purpose of this study is to find the highest dose of the investigational drug lirilumab that can be given safely with another investigational drug, nivolumab, in patients with advanced solid tumors that are no longer responding to standard therapies.
Nivolumab works by attaching to and blocking a molecule called PD-1. Lirilumab attaches to and blocks a group of molecules called KIR. PD-1 and KIR are proteins present mainly on immune system cells, and each controls part of the immune system by shutting it down. It is hoped that by binding to and inactivating these proteins, this drug combination can enhance the body’s ability to detect and destroy cancer cells.